Evidence map›Paper›PMID 27563453›Full record

ArticleJournal of gastrointestinal oncology2016

The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis.

Masayoshi Yada, Masayuki Miyazaki, Kenta Motomura, Akihide Masumoto, Makoto Nakamuta, Motoyuki Kohjima, Rie Sugimoto, Yoshifusa Aratake, Nobuhiko Higashi, Shusuke Morizono and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Role of lactate and lactate metabolism in liver diseases (Review).International journal of molecular medicine · 2024
    Review
  5. A New Prognostic Model Covering All Stages of Intrahepatic Cholangiocarcinoma.Journal of clinical and translational hepatology · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masayoshi YadaDepartment of Hepatology, Iizuka Hospital, Iizuka, Japan ;
Masayuki MiyazakiDepartment of Hepatology, Iizuka Hospital, Iizuka, Japan ;
Kenta MotomuraDepartment of Hepatology, Iizuka Hospital, Iizuka, Japan ;
Akihide MasumotoDepartment of Hepatology, Iizuka Hospital, Iizuka, Japan ;
Makoto NakamutaDepartment of Gastroenterology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan ;
Motoyuki KohjimaDepartment of Gastroenterology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan ;
Rie SugimotoDepartment of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan ;
Yoshifusa AratakeDepartment of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan ;
Nobuhiko HigashiDepartment of Gastroenterology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan ;
Shusuke MorizonoDepartment of Gastroenterology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan ;
Shinichiro TakaoDepartment of Gastroenterology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan ;
Naoki YamashitaDepartment of Hepatology, Steel Memorial Yawata Hospital, Fukuoka, Japan ;
Takeaki SatohDepartment of Gastroenterology, National Hospital Organization Kokura Medical Center, Fukuoka, Japan ;
Shinsaku YamashitaDepartment of Gastroenterology, National Hospital Organization Kokura Medical Center, Fukuoka, Japan ;
Masami KuniyoshiDepartment of Gastroenterology, Kyushu Rosai Hospital, Fukuoka, Japan ;
Kazuhiro KotohDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerum lactate dehydrogenase (LDH) levels could be a prognostic factor for sorafenib-treated patients with several types of solid tumor because it reflects hypoxic circumstances in aggressive tumors. For hepatocellular carcinoma (HCC), however, the prognostic role of LDH has been controversial. Liver fibrosis can potentially cause hypoxia in the liver, which has not been previously studied in the patients with advanced HCC. Thus, we aimed to analyze the prognostic role of LDH based on the degree of fibrosis.

methodsEighty-nine consecutive patients with HCC (Child-Pugh class A) who were treated using sorafenib were enrolled into this study. Pretreatment characteristics and changes in hepatic functional tests based on early response to sorafenib and serum LDH levels were analyzed. The degree of fibrosis was estimated using the aspartate aminotransferase (AST) to platelet ratio index (APRI), and the tumor response was evaluated after 3 months of sorafenib treatment.

resultsOverall, five patients discontinued sorafenib within 4 weeks. For the other 84 patients, those with progressive disease (PD) had significantly high pretreatment LDH levels, which correlated with the APRI score but not with the tumor stage. Multivariate logistic analysis revealed that older age and lower pretreatment LDH levels were independent prognostic factors for a better response to sorafenib. In patients who discontinued sorafenib early, three experienced acute liver failure accompanied with an increase in serum LDH.

conclusionsWe demonstrated that baseline serum LDH levels in HCC patients were affected by liver fibrosis but not by the tumor stage, and these LDH levels could be a marker for early response to sorafenib. A marked increase in serum LDH levels during sorafenib administration might also indicate subsequent acute liver failure. Close observation of serum LDH levels before and during sorafenib treatment could be useful in managing treatment of patients receiving this therapy.

Indexed as

acute liver failureHepatocellular carcinoma (HCC)lactate dehydrogenase (LDH)sorafenib

Identifiers

PMID27563453
PMCPMC4963370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.